Therefore, PD1 and CD28 expression by T-Exo may be a valuable tool in predicting the best responders to immunotherapy among patients with melanoma, while CD80 and CD86 levels may serve as prognostic biomarkers [24]. Here, CD80 is linked to melanoma.